BioCentury | Dec 15, 2020
Product Development

Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

A better understanding of responder profiles, a path to accelerated approval and proof that its degrader platform is not a one-trick pony were among the factors that nearly doubled Arvinas’ stock after the company presented...
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships.  The round, which includes Caris Life Sciences Inc.’s first equity...
BioCentury | Aug 9, 2019
Tools & Techniques

The next frontier for single-cell analysis

...cells and type I spiral ganglion neurons contributes to hearing loss, and these studies provided molecular profiles...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...that triggers cell death. The key will be finding the right conditions, either in tumor molecular profiles...
BioCentury | May 23, 2019
Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

...duration, he said. While polygenic risk scores don’t point to specific biological pathways, comparing the molecular profiles...
BioCentury | May 1, 2019
Company News

Caris aims to bridge gap between patients, precision trials with Pharmatech takeout

Caris' acquisition of Pharmatech, announced Wednesday, will allow the molecular profiling company to offer patients, physicians and drug developers an integrated approach to identifying and enrolling patients with rare mutations and other biomarkers in precision...
BioCentury | Apr 26, 2019
Clinical News

Cancer Research UK uses ctDNA profiling to stratify patients for early stage clinical trials

Cancer Research UK researchers used blood-based ctDNA profiling to match cancer patients with early stage clinical trials, reporting a preliminary efficiency of recruiting to a matched therapy of 11%. The researchers suggest that as more...
BioCentury | Apr 24, 2019
Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
BioCentury | Nov 30, 2018
Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

...an expanded access program. MMRF used data from the longitudinal CoMMPass trial to identify the molecular profiles...
...is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles...
BioCentury | Nov 29, 2018
Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

...an expanded access program. MMRF used data from the longitudinal CoMMPass trial to identify the molecular profiles...
...is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles...
Items per page:
1 - 10 of 132
BioCentury | Dec 15, 2020
Product Development

Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

A better understanding of responder profiles, a path to accelerated approval and proof that its degrader platform is not a one-trick pony were among the factors that nearly doubled Arvinas’ stock after the company presented...
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships.  The round, which includes Caris Life Sciences Inc.’s first equity...
BioCentury | Aug 9, 2019
Tools & Techniques

The next frontier for single-cell analysis

...cells and type I spiral ganglion neurons contributes to hearing loss, and these studies provided molecular profiles...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...that triggers cell death. The key will be finding the right conditions, either in tumor molecular profiles...
BioCentury | May 23, 2019
Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

...duration, he said. While polygenic risk scores don’t point to specific biological pathways, comparing the molecular profiles...
BioCentury | May 1, 2019
Company News

Caris aims to bridge gap between patients, precision trials with Pharmatech takeout

Caris' acquisition of Pharmatech, announced Wednesday, will allow the molecular profiling company to offer patients, physicians and drug developers an integrated approach to identifying and enrolling patients with rare mutations and other biomarkers in precision...
BioCentury | Apr 26, 2019
Clinical News

Cancer Research UK uses ctDNA profiling to stratify patients for early stage clinical trials

Cancer Research UK researchers used blood-based ctDNA profiling to match cancer patients with early stage clinical trials, reporting a preliminary efficiency of recruiting to a matched therapy of 11%. The researchers suggest that as more...
BioCentury | Apr 24, 2019
Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
BioCentury | Nov 30, 2018
Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

...an expanded access program. MMRF used data from the longitudinal CoMMPass trial to identify the molecular profiles...
...is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles...
BioCentury | Nov 29, 2018
Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

...an expanded access program. MMRF used data from the longitudinal CoMMPass trial to identify the molecular profiles...
...is a sequencing study that is following 1,000 patients for eight years to determine how molecular profiles...
Items per page:
1 - 10 of 132